(Reuters) – AstraZeneca said on Monday its cancer drugs Lynparza, developed with Merck & Co and Enhertu, developed with Japan’s Daiichi Sankyo, were recommended for the treatment of some high-risk breast cancers in the European Union.
(Reporting by Amna Karimi in Bengaluru; Editing by Rashmi Aich)
